Allergenic characterization of new mutant forms of Pru p 3 as new immunotherapy vaccines

C. Gómez-Casado, M. Garrido-Arandia, P. Gamboa, N. Blanca-López, G. Canto, J. Varela, J. Cuesta-Herranz, L. F. Pacios, A. Díaz-Perales, L. Tordesillas

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Nowadays, treatment of food allergy only considered the avoidance of the specific food. However, the possibility of cross-reactivity makes this practice not very effective. Immunotherapy may exhibit as a good alternative to food allergy treatment. The use of hypoallergenic molecules with reduced IgE binding capacity but with ability to stimulate the immune system is a promising tool which could be developed for immunotherapy. In this study, three mutants of Pru p 3, the principal allergen of peach, were produced based on the described mimotope and T cell epitopes, by changing the specific residues to alanine, named as Pru p 3.01, Pru p 3.02, and Pru p 3.03. Pru p 3.01 showed very similar allergenic activity as the wild type by in vitro assays. However, Pru p 3.02 and Pru p 3.03 presented reduced IgE binding with respect to the native form, by in vitro, ex vivo, and in vivo assays. In addition, Pru p 3.03 had affected the IgG4 binding capacity and presented a random circular dichroism, which was reflected in the nonrecognition by specific antibodies anti-Pru p 3. Nevertheless, both Pru p 3.02 and Pru p 3.03 maintained the binding to IgG1 and their ability to activate T lymphocytes. Thus, Pru p 3.02 and Pru p 3.03 could be good candidates for potential immunotherapy in peach-allergic patients.

Original languageEnglish
Article number385615
JournalClinical and Developmental Immunology
StatePublished - 2013
Externally publishedYes


Dive into the research topics of 'Allergenic characterization of new mutant forms of Pru p 3 as new immunotherapy vaccines'. Together they form a unique fingerprint.

Cite this